FyoniBio, Service branch of Glycotope GmbH

General information
FyoniBio, Service branch of Glycotope GmbH
Robert-Roessle-Str. 10
13125 Berlin, Berlin

Contact person: Henner Kollenberg, Managing Director
Company main phone: +49 (30) 94892600
Website:  www.fyonibio.com
Source of foundation:Subsidiary
Name of foundation source:Glycotope GmbH
Corporate description / mission:
FyoniBio, is a service branch of Glycotope has contract development services, which  provides solutions for supporting the customers in their biopharma development program, including:
• Cell line development in human GlycoExpress® and CHOnamite platform technologies
• USP Development, DSP development, analytical development
• In-depth PTM and protein analytics (N- and O-glycoprofiling, further PTM e.g. deamidation and oxidation, sequence confirmation and identification)
• Bioassay development services for different stages of drug development (cell viability & cytotoxicity, immuno-oncology, signaling, cytokine release testing)
• Clinical immune monitoring service (Immunogenicity assays, PK/PD assessment, biomarker analysis und GCLP
State of ownership: Private / independent
Headquarters: No
  • Biotechnology - R&D Services
  • Analytical services
  • CRO (Contract Research Organization)
Primary therapeutic areas:
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Genitourinary system / Urology
  • Neoplasms / cancer / oncology
Business model:
  • Research on contract basis
  • Service company
  • Subsidiary
Customer segments:
  • Large biotech & big pharma
  • Small biotech
  • Direct (own sales force)
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:2
Phase II:3
Description of products:
Process Development in GlycoExpress® and Rodent Cell Lines
USP-/ DSP-/ Analytical Development
Clinical Immunomonitoring
Immunogenicity Assays (Anti Drug Antibodies), PK/PD Assessment, Biomarker Analysis, etc.
Technology used:
Collaborations & Clients
Partnering strategy / collaborations:
Daiichi Sankyo
Airway Therapeutics
Fraunhofer-Institut für Zelltherapie und Immunologie